{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T09:06:18Z","timestamp":1770800778912,"version":"3.50.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.clml.2019.12.017","type":"journal-article","created":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T16:52:26Z","timestamp":1578502346000},"page":"316-323.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Survival of Patients With Second Primary Hodgkin Lymphoma"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3543-0305","authenticated-orcid":false,"given":"Justin","family":"Budnik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Doucette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8676-2855","authenticated-orcid":false,"given":"Michael T.","family":"Milano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0742-1740","authenticated-orcid":false,"given":"Louis S.","family":"Constine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2019.12.017_bib1","first-page":"7","article-title":"Cancer statistics, 2018","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2019.12.017_bib2","series-title":"SEER Survival Monograph: Cancer Survival Among Adults: US SEER Program, 1988\u20132001, Patient and Tumor Characteristics. NIH Publicaton 07-6215","year":"2007"},{"key":"10.1016\/j.clml.2019.12.017_bib3","first-page":"33","article-title":"Long-term survival in Hodgkin\u2019s disease","volume":"1","author":"Mauch","year":"1995","journal-title":"Cancer J Sci Am"},{"key":"10.1016\/j.clml.2019.12.017_bib4","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood.V93.3.761","article-title":"Problems in Hodgkin\u2019s disease management","volume":"93","author":"Aisenberg","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.12.017_bib5","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMe1502888","article-title":"Controversies in the treatment of early-stage Hodgkin\u2019s lymphoma","volume":"372","author":"Longo","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.12.017_bib6","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1200\/JCO.2003.07.131","article-title":"Long-term cause-specific mortality of patients treated for Hodgkin\u2019s disease","volume":"21","author":"Aleman","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.12.017_bib7","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.2016.70.9709","article-title":"Risk of second cancer in Hodgkin lymphoma survivors and influence of family history","volume":"35","author":"Sud","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.12.017_bib8","first-page":"1860","article-title":"Report of the committee on Hodgkin\u2019s disease staging classification","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2019.12.017_bib9","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.12.017_bib10","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1097\/MLR.0000000000000073","article-title":"Comparison of SEER treatment data with Medicare claims","volume":"54","author":"Noone","year":"2016","journal-title":"Med Care"},{"key":"10.1016\/j.clml.2019.12.017_bib11","series-title":"New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. NIH Publication 05-5302","article-title":"Chapter 2: methods","author":"Curtis","year":"2006"},{"key":"10.1016\/j.clml.2019.12.017_bib12","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/sim.5984","article-title":"The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"},{"key":"10.1016\/j.clml.2019.12.017_bib13","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/pst.433","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm Stat"},{"key":"10.1016\/j.clml.2019.12.017_bib14","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.radonc.2017.03.019","article-title":"Metastatic nasopharyngeal carcinoma: patterns of care and survival for patients receiving chemotherapy with and without local radiotherapy","volume":"124","author":"Rusthoven","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clml.2019.12.017_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.cllc.2019.02.017","article-title":"Second primary non\u2013small-cell lung cancer after head and neck cancer: a population-based study of clinical and pathologic characteristics and survival outcomes in 3597 patients [e-pub ahead of print]","author":"Budnik","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.clml.2019.12.017_bib16","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1002\/cncr.30164","article-title":"Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008","volume":"122","author":"Donin","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2019.12.017_bib17","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1200\/JCO.2017.72.4203","article-title":"Risk stratification for second primary lung cancer","volume":"35","author":"Han","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.12.017_bib18","doi-asserted-by":"crossref","first-page":"5088","DOI":"10.1200\/JCO.2010.29.5683","article-title":"Long-term survival among patients with Hodgkin\u2019s lymphoma who developed breast cancer: a population-based study","volume":"28","author":"Milano","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.12.017_bib19","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1080\/10428194.2017.1369063","article-title":"A\u00a0population-based study of prognosis and survival in patients with second primary thyroid cancer after Hodgkin lymphoma","volume":"59","author":"Chowdhry","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2019.12.017_bib20","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1158\/1078-0432.CCR-11-2097","article-title":"The use and interpretation of competing risks regression models","volume":"18","author":"Dignam","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2019.12.017_bib21","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/0959-8049(92)90018-W","article-title":"The EORTC trials for limited stage Hodgkin\u2019s disease. The EORTC Lymphoma Cooperative Group","volume":"28A","author":"Cosset","year":"1992","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2019.12.017_bib22","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1182\/blood-2011-09-378414","article-title":"A\u00a0retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era","volume":"119","author":"Evens","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.12.017_bib23","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1200\/JCO.2011.36.4703","article-title":"Lymphocyte-depleted classical Hodgkin\u2019s lymphoma: a comprehensive analysis from the German Hodgkin study group","volume":"29","author":"Klimm","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.12.017_bib24","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1093\/annonc\/mdr578","article-title":"Racial disparities in Hodgkin\u2019s lymphoma: a comprehensive population-based analysis","volume":"23","author":"Evens","year":"2012","journal-title":"Ann Oncol"},{"issue":"suppl 1","key":"10.1016\/j.clml.2019.12.017_bib25","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1093\/annonc\/mdi814","article-title":"ESMO Guidelines Task Force: ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of Hodgkin\u2019s disease","volume":"16","author":"Jost","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2019.12.017_bib26","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A\u00a0prognostic score for advanced Hodgkin\u2019s disease. International Prognostic Factors Project on Advanced Hodgkin\u2019s Disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.12.017_bib27","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2011.41.0910","article-title":"International prognostic score in advanced-stage Hodgkin\u2019s lymphoma: altered utility in the modern era","volume":"30","author":"Moccia","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.12.017_bib28","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.2016.70.9410","article-title":"Long-term follow-up of contemporary treatment in early-stage hodgkin lymphoma: updated analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 trials","volume":"35","author":"Sasse","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.12.017_bib29","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.12.017_bib30","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.2013.51.9298","article-title":"Omitting radiotherapy in early positron emission tomography\u2013negative stage I\/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"32","author":"Raemaekers","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.12.017_bib31","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1200\/JCO.1997.15.9.3060","article-title":"Clinical presentation and outcome in lymphocyte-predominant Hodgkin\u2019s disease","volume":"15","author":"Bodis","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.12.017_bib32","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3109\/10428199709051786","article-title":"Nodular lymphocyte predominance Hodgkin\u2019s disease: long-term observation reveals a continuous pattern of recurrence","volume":"26","author":"Orlandi","year":"1997","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2019.12.017_bib33","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1182\/blood-2017-10-772665","article-title":"Balancing risk and benefit in early-stage classical Hodgkin lymphoma","volume":"131","author":"Br\u00f6ckelmann","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.12.017_bib34","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1200\/JCO.1998.16.3.818","article-title":"Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin\u2019s disease. International Database on Hodgkin\u2019s Disease Overview Study Group","volume":"16","author":"Loeffler","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.12.017_bib35","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1200\/JCO.2014.58.7543","article-title":"Treatment selection and outcomes in early-stage classical Hodgkin lymphoma: analysis of the National Cancer Data Base","volume":"33","author":"Olszewski","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.12.017_bib36","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1200\/JCO.2003.07.113","article-title":"Treatment-related myelodysplasia and acute leukemia in non-Hodgkin\u2019s lymphoma patients","volume":"21","author":"Armitage","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.12.017_bib37","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1200\/JCO.2012.44.5791","article-title":"Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials","volume":"31","author":"Koontz","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.12.017_bib38","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1182\/blood-2014-05-579193","article-title":"Current survivorship recommendations for patients with Hodgkin lymphoma: focus on late effects","volume":"124","author":"Ng","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.12.017_bib39","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.3109\/10428194.2013.875169","article-title":"Impact of 18F-fluorodeoxyglucose positron emission tomography\/computed tomography staging in newly diagnosed classical Hodgkin lymphoma: fewer cases with stage I disease and more with skeletal involvement","volume":"55","author":"El-Galaly","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2019.12.017_bib40","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020300021?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020300021?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:33:42Z","timestamp":1761870822000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265020300021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S2152265020300021"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2019.12.017","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival of Patients With Second Primary Hodgkin Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2019.12.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}